An Indonesian study of the characteristics of the retinal vasculature found that the retinal vessel tortuosity (VT) was significantly higher and the fractal dimension (FD) was significantly lower in ...

In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the ...

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs. W. L. Gore and associates (Gore) announced the launch of its ...

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025. The Retina World Congress 2025, led ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

Ophthalmologist Tarek Hassan introduces new surgical approach for proliferative vitreoretinopathy, using precise small retinotomies instead of extensive retinal removal to improve patient outcomes.

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...

Ashvattha Therapeutics recently announced positive interim phase 2 results for migaldendranib (MGB). 1 MGB is described as a novel subcutaneously administered nanomedicine for the treatment of retinal ...

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss. A post hoc analysis of the GATHER1 and GATHER2 ...

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD. Seemi Khan, MD, MPH, MBA, Chief Medical Officer of ...